Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PhreesiaPHR +0.44%65 EV-to-EBITDA is 17.21 as of Aug. 05, 2026. GuruFocus rates PHR with a GF Score™ of 65/100 and a GF Value™ of $27.10 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 508 Healthcare Providers & Services companies, Phreesia ranks worse than 69.88% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Phreesia's enterprise value is $728.1 Mil.
Phreesia's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was $42.3 Mil. Therefore, Phreesia's EV-to-EBITDA for today is 17.21.
The historical rank and industry rank for Phreesia's EV-to-EBITDA or its related term are showing as below:
PHR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2048.31 Med: -14.8 Max: 2184.01
Current: 17.21
During the past 9 years, the highest EV-to-EBITDA of Phreesia was 2184.01. The lowest was -2048.31. And the median was -14.80.
PHR's EV-to-EBITDA is ranked worse than 69.88% of 508
companies
in the Healthcare Providers & Services industry
Industry Median: 11.015
vs PHR: 17.21
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Phreesia's share price for today is $11.49.
Phreesia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.150.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Phreesia's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Phreesia's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phreesia EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Phreesia's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Phreesia's EV-to-EBITDA falls into.
Phreesia's current Enterprise Value is $728.1 Mil.
Phreesia's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $42.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phreesia (PHR) has a EV-to-EBITDA of 17.21 as of Aug. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Phreesia. According to the industry distribution chart, Phreesia ranks #355 out of 508 companies in the Healthcare Providers & Services industry, placing it in the top 69.9%.
Is Phreesia's EV-to-EBITDA too high?
Phreesia's current EV-to-EBITDA is 17.21. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.02. Phreesia's value of 17.21 is 56.2% above this industry median. Based on the distribution chart, Phreesia ranks #355 out of 508 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Phreesia has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Phreesia's EV-to-EBITDA compare to MDRX and WEAV?
According to the Healthcare Providers & Services industry distribution chart, Phreesia ranks #355 out of 508 companies for EV-to-EBITDA. This places Phreesia in the lower half of its industry. The industry median EV-to-EBITDA is 11.02. Phreesia's value of 17.21 is 56.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.02, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phreesia's current EV-to-EBITDA of 17.21 is 56.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Phreesia. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phreesia's current EV-to-EBITDA is 17.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phreesia stock overvalued right now?
Based on GuruFocus' analysis, Phreesia (PHR) is currently considered Possible Value Trap. The stock's GF Value™ is $27.10, compared to a current price of $11.49 — trading 57.6% below its estimated fair value. The current EV-to-EBITDA is 17.21 and 56.2% above the Healthcare Providers & Services industry median of 11.02. Phreesia's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Phreesia (PHR), the current EV-to-EBITDA is 17.21 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phreesia (PHR) Overvalued in 2026?
Based on GuruFocus' analysis, Phreesia stock appears to be undervalued.
The current stock price of $11.49 is trading 57.6% below its estimated GF Value™ of $27.10.
GuruFocus considers Phreesia to be Possible Value Trap.
Key valuation signals for PHR:
EV-to-EBITDA: 17.21
GF Value™: $27.10 vs. price of $11.49 (57.6% below fair value)
Industry Position: 56.2% above the Healthcare Providers & Services median (#355 of 508)
No single metric tells the full story. See the PHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phreesia Inc is a provides an integrated software, payments, and engagement platform designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and patient health outcomes. Its platform is embedded directly into provider workflows and patient interactions, enabling healthcare organizations to activate patients, streamline administrative processes, and improve financial performance across the care continuum. The group serves a diverse group of healthcare organizations, including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest, and not-for-profit and other organizations.
65GF Score
Get the complete analysis for PHR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHR has been successfully added to your 
